|
[18F]AlF radioconjugate
|
Serum stability at 1 h (%)a
|
T:B ratio
|
T:M ratio
|
Time point p.i. (h)b
|
References
|
|---|
|
[18F]AlF-NODAGA-RM1
|
> 90
|
10.29
|
14.58
|
2
|
Liu et al. (2013)
|
|
[18F]AlF-NODAGA-AMBA
|
72.5
|
–
|
8c
|
2
|
Liu et al. (2013)
|
|
[18F]AlF-NOTA-8-Aoc-BBN(7–14)NH2
|
–
|
49.51
|
–
|
1
|
Dijkgraaf et al. (2012)
|
|
[18F]AlF-NOTA-4,7-lanthionine-BBN
|
> 80 (human serum)
|
0.71
|
9.11
|
2
|
Carlucci et al. (2015)
|
|
[18F]AlF-NOTA-2,6-lanthionine-BBN
|
> 80 (human serum)
|
1.24
|
6.7
|
2
|
Carlucci et al. (2015)
|
|
[18F]AlF-NOTA(6)-MATBBN
|
> 95 (human serum)
|
9.44
|
30.70
|
1
|
Pan et al. (2014)
|
|
[18F]AlF-JMV5132
|
–
|
106
|
305c
|
1
|
Chatalic et al. (2014)
|
|
[18F]AlF-NOTA-P2-RM26
|
> 98
|
87
|
159
|
3
|
Varasteh et al. (2013)
|
- aIntact parent radioconjugate in mouse serum after 1 h incubation, unless stated otherwise
- bThe timepoint post-injection where T:B and T:M data is reported. T:B = tumour-to-blood ratio and T:M = tumour-to-muscle ratio calculated from ex vivo biodistribution data presented in the original manuscript and represented as a mean value
- cEstimated from graphical data in the original manuscript
